Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model

Monoclonal antibodies that block inhibitory immune checkpoint molecules and enhance anti-tumor responses show clinical promise in advanced solid tumors. Most of the preliminary evidence on therapeutic efficacy of immune checkpoint blockers comes from studies in melanoma, lung and renal cancer. To te...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Main Authors: Mony, Jyothi Thyagabhavan, Zhang, Lixin, Ma, Tianzhou, Grabosch, Shannon, Tirodkar, Tejas S., Brozick, Joan, Tseng, George, Elishaev, Esther, Edwards, Robert P., Huang, Xin, Vlad, Anda M.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4545381/
https://ncbi.nlm.nih.gov/pubmed/25998800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-015-1712-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados